

**AMENDMENTS TO THE CLAIMS**

**Listing of Claims:**

1-8. (Cancelled)

9. (Currently Amended) A method for inhibiting synovial cell growth, comprising administering to a patient in need thereof a pharmaceutical composition comprising humanized PM-1 antibody and a physiologically acceptable carrier, wherein said humanized PM-1 antibody comprises

(A) L chain of an antibody to a human IL-6 receptor, comprising the amino acid sequence of SEQ ID NO: 20;

~~CDR1<sup>1</sup>, CDR2<sup>1</sup> and CDR3<sup>1</sup> which represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:~~

~~CDR1<sup>1</sup>—Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn (SEQ ID NO: 2)~~

~~CDR2<sup>1</sup>—Tyr Thr Ser Arg Leu His Ser (SEQ ID NO: 3)~~

~~CDR3<sup>1</sup>—Gln Gln Gly Asn Thr Leu Pro Tyr Thr (SEQ ID NO: 4);~~

(B) H chain of an antibody to the human IL-6 receptor, comprising the amino acid sequence of SEQ ID NO: 18.

~~CDR1<sup>2</sup>, CDR2<sup>2</sup> and CDR3<sup>2</sup> which represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:~~

~~CDR1<sup>2</sup>—Ser Asp His Ala Trp Ser (SEQ ID NO: 10)~~

~~CDR2<sup>2</sup>—Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro Ser Leu Lys Ser (SEQ ID NO: 11)~~

~~CDR3<sup>2</sup>—Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr (SEQ ID NO: 12).~~

10-12. (Cancelled)

13. (Previously Presented) A method of treating chronic rheumatoid arthritis, comprising administering to a patient in need thereof a pharmaceutical composition comprising humanized PM-1 antibody and a physiologically acceptable carrier, wherein said humanized PM-1 antibody comprises:

(A) L chain of an antibody to a human IL-6 receptor, comprising the amino acid sequence of SEQ ID NO: 20;

~~CDR1<sup>+</sup>, CDR2<sup>+</sup> and CDR3<sup>+</sup> which represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:~~

~~CDR1<sup>+</sup> Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn (SEQ ID NO: 2)~~

~~CDR2<sup>+</sup> Tyr Thr Ser Arg Leu His Ser (SEQ ID NO: 3)~~

~~CDR3<sup>+</sup> Gln Gln Gly Asn Thr Leu Pro Tyr Thr (SEQ ID NO: 4);~~

(B) H chain of an antibody to the human IL-6 receptor, comprising the amino acid sequence of SEQ ID NO: 18.

~~CDR1<sup>2</sup>, CDR2<sup>2</sup> and CDR3<sup>2</sup> which represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:~~

~~CDR1<sup>2</sup> Ser Asp His Ala Trp Ser (SEQ ID NO: 10)~~

~~CDR2<sup>2</sup> Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro Ser Leu Lys Ser (SEQ ID NO: 11)~~

~~CDR3<sup>2</sup> Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr (SEQ ID NO: 12).~~

14. (Previously Presented) The method according to claim 13, wherein the antibody suppresses abnormal growth of synovial cells.

15-25. (Cancelled)